Funding for Global Research and Training
The Center for Global Health helps reduce the global burden of cancer by strengthening research capacity through funding and training. Below you will find the most recent funding opportunities that are relevant to our work.
Current Funding Opportunities
Learn more about current international cancer research and cancer control funding opportunities developed by CGH, or supported by NCI in collaboration with other NIH Institutes and Centers or research organizations.
Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions
Notice Number: NOT-DE-21-010
This Notice of Special Interest (NOSI) encourages research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.
NCI also encourages applications to develop context-appropriate tools for use in low- and middle-income countries (LMICs), given that oral cancer burden is high in other parts of the world, especially in Asia. Incidence is driven by tobacco smoking and alcohol use, but also smokeless tobacco and betel quid, which are major carcinogenic exposures in LMICs. Populations in LMICs can benefit from new approaches for discriminating pre-cancer and cancer from non-malignancy oral lesions as well as approaches for secondary prevention/treatment of pre-cancer that can be performed by health workers at the point-of-care. Applicants are strongly encouraged to contact the Scientific/Research contacts listed in Section VII to discuss the relevance of the proposed studies before submitting the application.
Mobile Health: Technology and Outcomes in Low- and Middle-Income Countries (R21/R33 - Clinical Trial Optional)
Funding Announcement: PAR-21-303
The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes and strengthen mHealth research capacity in LMICs.
This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.
SBIR Contract Topic 440 - Cancer Prevention and Diagnosis Technologies for Low-resource Settings (with HPV Dx set aside)
Topic Number: NIH/NCI 440
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) invites small business concerns (SBCs) to submit research proposals under this Small Business Innovation Research (SBIR) Contract Solicitation. The purpose of this solicitation is to provide funding opportunities for SBCs to develop cost-effective and affordable technologies for cancer prevention, early detection, and/or diagnosis that target low-resource settings, both internationally and within the US. It will allow applications to any specific cancer type, however, four cancer types (tissues) are of particular interest because they are highly amenable to prevention, early detection, and diagnosis in low-resource settings. The four cancer types of interest are: cancers of the cervix, colon/rectum, esophagus, and oral cavity. These four cancer types are given a high priority because the introduction of affordable and cost-effective technologies for cancer prevention early detection and diagnosis is likely to have an especially strong impact to reduce the burden of these cancers in low-resource settings.
For cervical cancer, one of the goals for this initiative is to support the development of new alternatives to standard lab-based HPV testing to the market that are both in a form factor as well as price point that will enable primary screening paradigms based on self-collected cervicovaginal specimens to be established globally. Specifically, at- or near-patient nucleic acid amplification approaches are needed that enable rapid detection and genotyping for HPV. Receipt date: October 28, 2021, 5:00 p.m. Eastern Daylight Time
Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings
Notice Number: NOT-CA-21-062
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) encourage SBIR/STTR grant applications from small business concerns (SBCs) in response to SBIR/STTR Omnibus Solicitations proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US.
Specifically, this NOSI encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in low-resource settings, including remote or underserved populations within or outside the US. The technologies may include but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to prevention, diagnosis, or treatment options available in the local health system. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.
Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)
Funding Announcement: RFA-CA-21-056
This Funding Opportunity Announcement (FOA) supports Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure. Specifically, this FOA solicits applications that will identify, understand, and develop strategies to address barriers to the adoption, integration, and sustainability of evidence-based cancer control interventions among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control for PLWH worldwide. Responsive applications should include multi-disciplinary teams of researchers with expertise in HIV, cancer, and implementation science to address the cancer control needs of PLWH populations specific to the proposed LMIC context.
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)
Funding Announcement: RFA-CA-21-030
This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.
Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)
Funding Announcement: RFA-CA-20-031
The purpose of this Funding Opportunity Announcement is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the U.S.-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs.
International Research Scientist Development Award (IRSDA) (K01)
Funding Announcements: PAR-21-104 (Independent Clinical Trial Not Allowed) PAR-21-105 (Independent Clinical Trial Required)
The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty for an intensive, mentored research career development experience in a low- or middle-income country (LMIC) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors.
The East Asia Science and Innovation Area Joint Research Program
Apply at: https://www.the-easia.org/jrp/
The East Asia Science and Innovation Area Joint Research Program, or e-ASIA JRP call for applications is now open. The e-Asia JRP is a multilateral international joint initiative between a number of public funding organizations of the East Asia Summit (EAS) member countries. e-ASIA JRP works to formulate and support international joint research in the East Asian region as well as research exchanges through workshops and other activities. Research projects are selected through open calls for proposals and subsequently supported by co-funding from the participating agencies. The NCI is participating in the e-ASIA JRP through in-kind and re-budgeting only and does not anticipate new awards to support e-ASIA projects, though new funding for international collaborative partners is available from several participating funding agencies. The application form and more information about the JRP can be found here: https://www.the-easia.org/jrp/. For additional information about the solicitation guidelines, please visit https://www.the-easia.org/jrp/pdf/cfp10/guideline_10th_health.pdf.
Notice of Special Interest (NOSI): Innovative Molecular Analysis Technologies for Low-Resource Settings Globally
Notice Number: NOT-CA-21-025
With this NOSI, the NCI Center for Global Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) program activities to stimulate exploratory research on technology platforms relevant for global oncology and appropriate for use in low-resource settings globally. CGH is prepared to support highly meritorious IMAT R21 applications with the goal of helping drive innovation in this field and to enrich the pool of investigators participating in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program. Notice: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-21-025.html
Notice of Special Interest: Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program
Notice Number: NOT-OD-21-021
The AKA-NIH Partnership Program seeks to encourage increased collaborative research between investigators in the U.S. and Finland. This is to be facilitated through the submission of grant applications from U.S. institutions that include collaboration with Finnish investigators selected by AKA to participate in the joint research program. NIH will support the project through regular investigator-initiated NIH application processes and review. AKA will fully fund Finnish investigators on collaborative grant applications that are selected for funding by participating NIH Institutes and Centers (ICs), while NIH will fund the U.S. component. Examples of research support can be found at https://grants.nih.gov/grants/guide/notice-files/not-od-21-021.html.
Notice of Special Interest (NOSI): Advancing Head and Neck Cancer Early Detection Research (AHEAD)
Notice Number: NOT-CA-20-031
The purpose of this Notice is to inform potential applicants of the special interest of the National Cancer Institute in encouraging the submission of applications that advance early detection of head and neck cancer (HNC) by applying genomics, epigenomics, transcriptomics, proteomics, and molecular signatures to clinical studies for differentiating benign lesions from malignant ones. The initiative also encourages novel basic research for HNC cancer prevention as well as the development of molecular markers to combine with current available HNC detection methods for increasing sensitivity and specificity.
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments
This Notice seeks to inform potential applicants of the interest of the National Cancer Institute (NCI) in supporting implementation research related to cancer prevention and control in low- and middle-income countries (LMICs) and in low-resource settings. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings. The research projects on which these applications will be based should be focused on dissemination and implementation research for the primary and secondary prevention of cancer in LMICs and/or in populations facing conditions of vulnerability in high-income countries.
Interested applicants must submit applications for this initiative using one of the following Dissemination and Implementation Research in Health funding opportunity announcements: PAR-19-274 (R01 Clinical Trial Optional); PAR-19-275 (R21 Clinical Trial Optional); PAR-19-276 (R03 Clinical Trial Not Allowed). For more information visit: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-025.html.
The purpose of this funding opportunity announcement is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. PAR-19-194 (R21 for early stage research); PAR-19-193 (R01 for mature projects). Examples of Applications: (RO1, R21s).
Dissemination and Implementation Research in Health (Clinical Trial Optional)
This funding opportunity encourages research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. PAR-19-274 (R01); PAR-19-275 (R21).
This funding opportunity encourages research grant applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement evidence-based health practices for public health, clinical practice, and community settings.
International Research Scientist Development Award (K01)
This funding opportunity supports intensive, mentored research career development for early stage investigators committed to a cancer research career. PAR-18-539 (Independent clinical trial not allowed). PAR-18-540 (Independent clinical trial required). For additional information, please visit Frequently Asked Questions for the International Research Scientist Development Award.
This funding opportunity supports U.S.- Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region, aligned with existing, publicly available U.S. datasets.
These funding opportunities highlight research initiatives that align with the efforts of the Cancer Moonshot. Supported with existing or 21st Century Cures Act funds, featured announcements include open funding opportunities.
This funding opportunity supports high quality scientific conferences that are relevant to the NIH's mission and to the public health.
Previously Funded Initiatives
Learn more about CGH’s previously funded research grants and initiatives. Download list of CGH previously funded initiatives.
Learn more about training opportunities available to U.S. and international students, scientists, and health care professionals.
The Short-Term Scientist Exchange Program at the Center for Global Health, National Cancer Institute, promotes collaborative research between researchers at the NCI and foreign cancer researchers.
This program offers two short-term cancer prevention training courses in Rockville, MD to international scientists and healthcare professionals from LMICs and the All-Ireland Cancer Consortium (AICC).